Topics

FDA Grants Priority Review to Tucatinib for HER2-Positive Breast Cancer Treatment

19:00 EST 13 Feb 2020 | Cancer Networks

The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer.

Original Article: FDA Grants Priority Review to Tucatinib for HER2-Positive Breast Cancer Treatment

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Tucatinib for HER2-Positive Breast Cancer Treatment"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...